Skip to main content

Table 1 Baseline characteristics of C3GN and C3 Control patients

From: The impact of reclassification of C3 predominant glomerulopathies on diagnostic accuracy, outcome and prognosis in patients with C3 glomerulonephritis

Category C3GN
(n = 10)
C3 Controls
(n = 21)
p value
Gender (% Male) 50 (n = 5) 33(n = 7) 0.4
Age at diagnosis (years) 57 (41–61) 55 (35–65) 0.9
SBP (mmHg) 140 (122–160) 145 (128–154) 0.9
DBP (mmHg) 83 (68–89) 80 (70–87) 0.7
Caucasian (%) 60 (n = 6) 85 (n = 18) 0.08
Asian (%) 0 10 (n = 2) 0.2
Aboriginal (%) 0 0
Torres Strait Islander (%) 10 (n = 1) 5 (n = 1) 0.04
Hispanic (%) 0 5 0.3
Black (%) 0 0
AKI (%) 60 (n = 6) 57 (n = 12) 0.9
AKI needing acute HD (%) 30 (n = 30) 14 (n = 3) 0.3
Nephrotic syndrome (%) 30 (n = 30) 10 (n = 2) 0.3
Haematuria (%) 100 (n = 10) 80 (n = 17) 0.3
uPCR at diagnosis (mg/mmol) 300 (106–947) 154 (55–573) 0.7
Creatinine at diagnosis (umol/L) 253 (103–333) 127 (105–182) 0.01
Complement levels (C3) 0.91 (0.56–1.04) 1.15 (0.93–1.39) 0.4
Low Complement levels (%) 20 19 1
ANA titre (dilution) 80 (80–329) 80 (0–200) 0.6
ANCA (% positive) 0 20 0.2
C3Nef/CFH/CFb antibody (%) 0 (n = 0/2) 0 not tested
Significant light chain ratio (% positive) 0 (n = 0/4) 0 (n = 0/7)
ASOT titre (+) > 200 IU (%) 0 (n = 0/2) 50 (n = 1/2) 0.2
  1. All data reported in median plus IQR unless otherwise indicated